# A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

> **NCT05648214** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 172 (estimated)

## Conditions studied

- Healthy Volunteers
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

## Interventions

- **DRUG:** ALN-PNP
- **DRUG:** Placebo (PB)

## Key facts

- **NCT ID:** NCT05648214
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-27
- **Primary completion:** 2027-08-10
- **Final completion:** 2027-08-10
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05648214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05648214, "A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05648214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*